ЭFFICACY AND TOLERABILITY OF LENVATINIB IN RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
loading.default
item.page.files
item.page.date
item.page.authors
item.page.journal-title
item.page.journal-issn
item.page.volume-title
item.page.publisher
Western European Studies
item.page.abstract
The introduction of tyrosine kinase inhibitors into clinical practice has significantly improved treatment outcomes for patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). Lenvatinib is recommended as a first-line drug for this category of patients